Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NZE8
UPID:
RM35_HUMAN
Alternative names:
39S ribosomal protein L35, mitochondrial
Alternative UPACC:
Q9NZE8; A6NKV6; B2RB93; Q658U7; Q8WWA2
Background:
The Large ribosomal subunit protein bL35m, also known as 39S ribosomal protein L35, mitochondrial, plays a crucial role in protein synthesis within mitochondria. Its involvement in the mitochondrial ribosome's structure suggests a fundamental contribution to mitochondrial function and cellular energy metabolism.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein bL35m could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis positions it as a key target for interventions aimed at mitochondrial diseases and disorders related to cellular energy metabolism.